Isolation and characterization of the rolipram-sensitive cyclic AMP-specific phosphodiesterase (type IV PDE) in human term myometrium. 1994

M J Leroy, and C Lugnier, and J Merezak, and G Tanguy, and S Olivier, and A Le Bec, and F Ferré
INSERM Unité 361, Maternité Baudelocque, Paris, France.

On the basis of the potencies of classical selective modulators of cyclic nucleotide phosphodiesterase (PDE) activities, five cyclic nucleotide PDE isoforms have been isolated and characterized in the cytosolic fraction of human term myometrium. By means of successive ion-exchange chromatographies, a calcium-calmodulin sensitive isoform, a cyclic GMP-stimulated isoform, a cyclic GMP-inhibited isoform, a rolipram-sensitive cyclic AMP-specific isoform and a cyclic GMP-specific isoform, corresponding to PDE I, PDE II, PDE III, PDE IV and PDE V, respectively, have been identified. We found that near term, human myometrium contains a higher proportion of the rolipram-sensitive type IV PDE isoform (about 50% of total cyclic AMP hydrolytic activity) than the type III cyclic GMP-inhibited PDE isoform (only 10%). Type IV PDE displays simple Michaelis-Menten kinetics with a high affinity for cyclic AMP (Km approximately 4.4 microM) and is selectively and competitively inhibited by rolipram (K(i) approximately 0.9 microM) and Ro 20-1724 (K(i) approximately 2.6 microM). The predominance of type IV PDE at the end of pregnancy suggests that this isoform contributes, via a modulation of the intracellular cyclic AMP level, to local control of uterine motility and thus could help the myometrium prepare for pronounced contractile activity at the time of parturition.

UI MeSH Term Description Entries
D007527 Isoenzymes Structurally related forms of an enzyme. Each isoenzyme has the same mechanism and classification, but differs in its chemical, physical, or immunological characteristics. Alloenzyme,Allozyme,Isoenzyme,Isozyme,Isozymes,Alloenzymes,Allozymes
D007700 Kinetics The rate dynamics in chemical or physical systems.
D009215 Myometrium The smooth muscle coat of the uterus, which forms the main mass of the organ. Uterine Muscle,Muscle, Uterine,Muscles, Uterine,Uterine Muscles
D010726 Phosphodiesterase Inhibitors Compounds which inhibit or antagonize the biosynthesis or actions of phosphodiesterases. Phosphodiesterase Antagonists,Phosphodiesterase Inhibitor,Phosphoric Diester Hydrolase Inhibitors,Antiphosphodiesterases,Inhibitor, Phosphodiesterase
D011247 Pregnancy The status during which female mammals carry their developing young (EMBRYOS or FETUSES) in utero before birth, beginning from FERTILIZATION to BIRTH. Gestation,Pregnancies
D002851 Chromatography, High Pressure Liquid Liquid chromatographic techniques which feature high inlet pressures, high sensitivity, and high speed. Chromatography, High Performance Liquid,Chromatography, High Speed Liquid,Chromatography, Liquid, High Pressure,HPLC,High Performance Liquid Chromatography,High-Performance Liquid Chromatography,UPLC,Ultra Performance Liquid Chromatography,Chromatography, High-Performance Liquid,High-Performance Liquid Chromatographies,Liquid Chromatography, High-Performance
D002852 Chromatography, Ion Exchange Separation technique in which the stationary phase consists of ion exchange resins. The resins contain loosely held small ions that easily exchange places with other small ions of like charge present in solutions washed over the resins. Chromatography, Ion-Exchange,Ion-Exchange Chromatography,Chromatographies, Ion Exchange,Chromatographies, Ion-Exchange,Ion Exchange Chromatographies,Ion Exchange Chromatography,Ion-Exchange Chromatographies
D003600 Cytosol Intracellular fluid from the cytoplasm after removal of ORGANELLES and other insoluble cytoplasmic components. Cytosols
D004789 Enzyme Activation Conversion of an inactive form of an enzyme to one possessing metabolic activity. It includes 1, activation by ions (activators); 2, activation by cofactors (coenzymes); and 3, conversion of an enzyme precursor (proenzyme or zymogen) to an active enzyme. Activation, Enzyme,Activations, Enzyme,Enzyme Activations
D004795 Enzyme Stability The extent to which an enzyme retains its structural conformation or its activity when subjected to storage, isolation, and purification or various other physical or chemical manipulations, including proteolytic enzymes and heat. Enzyme Stabilities,Stabilities, Enzyme,Stability, Enzyme

Related Publications

M J Leroy, and C Lugnier, and J Merezak, and G Tanguy, and S Olivier, and A Le Bec, and F Ferré
January 1994, Gene,
M J Leroy, and C Lugnier, and J Merezak, and G Tanguy, and S Olivier, and A Le Bec, and F Ferré
December 1994, The Biochemical journal,
M J Leroy, and C Lugnier, and J Merezak, and G Tanguy, and S Olivier, and A Le Bec, and F Ferré
January 1999, Brain research. Developmental brain research,
M J Leroy, and C Lugnier, and J Merezak, and G Tanguy, and S Olivier, and A Le Bec, and F Ferré
April 1993, The Biochemical journal,
M J Leroy, and C Lugnier, and J Merezak, and G Tanguy, and S Olivier, and A Le Bec, and F Ferré
July 1993, Gene,
M J Leroy, and C Lugnier, and J Merezak, and G Tanguy, and S Olivier, and A Le Bec, and F Ferré
November 1990, Journal of cardiovascular pharmacology,
M J Leroy, and C Lugnier, and J Merezak, and G Tanguy, and S Olivier, and A Le Bec, and F Ferré
June 1990, Molecular and cellular biology,
M J Leroy, and C Lugnier, and J Merezak, and G Tanguy, and S Olivier, and A Le Bec, and F Ferré
February 2002, Biochemical pharmacology,
M J Leroy, and C Lugnier, and J Merezak, and G Tanguy, and S Olivier, and A Le Bec, and F Ferré
January 1991, Agents and actions. Supplements,
M J Leroy, and C Lugnier, and J Merezak, and G Tanguy, and S Olivier, and A Le Bec, and F Ferré
October 1994, International journal of immunopharmacology,
Copied contents to your clipboard!